[go: up one dir, main page]

CY1124084T1 - Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων - Google Patents

Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων

Info

Publication number
CY1124084T1
CY1124084T1 CY20211100366T CY211100366T CY1124084T1 CY 1124084 T1 CY1124084 T1 CY 1124084T1 CY 20211100366 T CY20211100366 T CY 20211100366T CY 211100366 T CY211100366 T CY 211100366T CY 1124084 T1 CY1124084 T1 CY 1124084T1
Authority
CY
Cyprus
Prior art keywords
derivatives
pyridinyltriazole
amide substituted
compounds
prevention
Prior art date
Application number
CY20211100366T
Other languages
English (en)
Inventor
Marie-Pierre Collin
Peter Kolkhof
Thomas Neubauer
Chantal FÜRSTNER
Elisabeth Pook
Klemens Lustig
Anja BUCHMÜLLER
Hanna Tinel
Karoline DRÖBNER
Thomas MONDRITZKI
Heiko Schirmer
Axel Kretschmer
Carsten Schmeck
Pierre Wasnaire
Hana CERNECKA
Matthias Beat WITTWER
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1124084T1 publication Critical patent/CY1124084T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε καινοτόμα παράγωγα 5-(καρβοξαμιδο)-1-πυριδινυλο-1,2,4-τριαζόλης, σε διαδικασίες για την παρασκευή αυτών των ενώσεων, σε φαρμακευτικές συνθέσεις που περιέχουν αυτές τις ενώσεις, και στη χρήση αυτών των ενώσεων ή συνθέσεων για τη θεραπευτική αντιμετώπιση και/ή πρόληψη παθήσεων, συγκεκριμένα για τη θεραπευτική αντιμετώπιση και/ή πρόληψη νεφρικών και καρδιαγγειακών παθήσεων.
CY20211100366T 2016-05-03 2021-04-27 Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων CY1124084T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03
PCT/EP2017/060356 WO2017191102A1 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Publications (1)

Publication Number Publication Date
CY1124084T1 true CY1124084T1 (el) 2022-05-27

Family

ID=55910850

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100366T CY1124084T1 (el) 2016-05-03 2021-04-27 Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων

Country Status (42)

Country Link
US (4) US9988367B2 (el)
EP (1) EP3452463B1 (el)
JP (1) JP6932140B2 (el)
KR (1) KR20190003655A (el)
CN (2) CN113121504A (el)
AR (1) AR108262A1 (el)
AU (1) AU2017259870B2 (el)
BR (1) BR112018072542A2 (el)
CA (1) CA3022749A1 (el)
CL (1) CL2018003105A1 (el)
CO (1) CO2018011933A2 (el)
CR (1) CR20180522A (el)
CU (1) CU24567B1 (el)
CY (1) CY1124084T1 (el)
DK (1) DK3452463T3 (el)
DO (1) DOP2018000240A (el)
EA (1) EA035596B1 (el)
EC (1) ECSP18081881A (el)
ES (1) ES2866109T3 (el)
GE (1) GEP20207158B (el)
HR (1) HRP20210648T1 (el)
HU (1) HUE053908T2 (el)
IL (1) IL262557B (el)
JO (1) JOP20170105B1 (el)
LT (1) LT3452463T (el)
MA (1) MA44851B1 (el)
MX (1) MX381787B (el)
NI (1) NI201800115A (el)
PE (1) PE20190116A1 (el)
PH (1) PH12018502268A1 (el)
PL (1) PL3452463T3 (el)
PT (1) PT3452463T (el)
RS (1) RS61771B1 (el)
SG (1) SG11201809752VA (el)
SI (1) SI3452463T1 (el)
SV (1) SV2018005771A (el)
TN (1) TN2018000368A1 (el)
TW (1) TWI772295B (el)
UA (1) UA123791C2 (el)
UY (1) UY37220A (el)
WO (1) WO2017191102A1 (el)
ZA (1) ZA201808131B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CA3022755A1 (en) * 2016-05-03 2017-11-09 Carsten Schmeck Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
HRP20201746T1 (hr) 2016-05-03 2020-12-25 Bayer Pharma Aktiengesellschaft Aromatski derivati sulfonamida
WO2017191104A1 (de) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
US10954197B2 (en) * 2017-03-08 2021-03-23 Yogee's Bioinnovations Private Limited Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
WO2019032746A1 (en) 2017-08-08 2019-02-14 Fresenius Medical Care Holdings, Inc. SYSTEMS AND METHODS FOR TREATING AND ESTIMATING THE PROGRESSION OF CHRONIC RENAL DISEASE
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
US11173151B2 (en) 2017-10-24 2021-11-16 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
UA126456C2 (uk) 2017-10-24 2022-10-05 Баєр Акціенгезельшафт Проліки заміщених триазольних похідних та їх застосування
CA3084411A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
US20210016350A1 (en) * 2018-04-10 2021-01-21 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
KR20220113782A (ko) * 2019-12-24 2022-08-16 도쿄엘렉트론가부시키가이샤 성막 방법 및 성막 시스템
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
WO2024118667A1 (en) * 2022-11-29 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Eif4a1 inhibitors with antitumor activity

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1992020662A1 (en) 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
JP3589633B2 (ja) 1997-12-17 2004-11-17 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
AU749204B2 (en) 1998-07-24 2002-06-20 Bayer Aktiengesellschaft Substituted benzoylcyclohexandiones
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
HRP20010716A2 (en) 1999-04-01 2002-12-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP4673295B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
WO2005006892A2 (en) 2003-06-27 2005-01-27 Berglin Corporation Of Washington Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits
CA2551038C (en) * 2003-12-22 2010-04-27 Pfizer Inc. Triazole derivatives as vasopressin antagonists
CA2557721A1 (en) 2004-03-08 2005-10-20 Wyeth Ion channel modulators
AU2005220911A1 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
MX2012009862A (es) 2010-02-27 2012-09-12 Bayer Ip Gmbh Ariltriazolonas ligadas a bisarilo y su uso.
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AU2011275825A1 (en) 2010-07-09 2013-02-07 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
JP5787237B2 (ja) * 2010-10-01 2015-09-30 大正製薬株式会社 １，２，４−トリアゾロン誘導体
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2828257B1 (en) 2012-03-22 2017-07-26 Biota Europe Ltd Antibacterial compounds
AU2015342017B2 (en) 2014-11-03 2020-02-06 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CA3022755A1 (en) * 2016-05-03 2017-11-09 Carsten Schmeck Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191104A1 (de) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen

Also Published As

Publication number Publication date
CO2018011933A2 (es) 2018-11-22
TN2018000368A1 (en) 2020-06-15
DOP2018000240A (es) 2019-03-15
MA44851A (fr) 2019-03-13
AU2017259870A1 (en) 2018-11-15
US20200017473A1 (en) 2020-01-16
KR20190003655A (ko) 2019-01-09
MX2018013335A (es) 2019-05-09
PT3452463T (pt) 2021-04-28
CN109415347B (zh) 2021-05-07
SG11201809752VA (en) 2018-12-28
CA3022749A1 (en) 2017-11-09
TW201806941A (zh) 2018-03-01
NI201800115A (es) 2019-03-14
HRP20210648T1 (hr) 2021-05-28
WO2017191102A1 (en) 2017-11-09
CR20180522A (es) 2019-01-15
JP2019514945A (ja) 2019-06-06
SI3452463T1 (sl) 2021-07-30
EA035596B1 (ru) 2020-07-14
ZA201808131B (en) 2021-05-26
US20180251447A1 (en) 2018-09-06
US11091463B2 (en) 2021-08-17
SV2018005771A (es) 2019-01-04
CN113121504A (zh) 2021-07-16
IL262557B (en) 2022-01-01
EA201892505A1 (ru) 2019-04-30
DK3452463T3 (da) 2021-04-26
PL3452463T3 (pl) 2021-08-09
RS61771B1 (sr) 2021-05-31
IL262557A (en) 2018-12-31
CL2018003105A1 (es) 2019-02-15
PH12018502268A1 (en) 2019-07-15
US9988367B2 (en) 2018-06-05
CN109415347A (zh) 2019-03-01
CU20180134A7 (es) 2019-06-04
AU2017259870B2 (en) 2021-07-15
TWI772295B (zh) 2022-08-01
AR108262A1 (es) 2018-08-01
PE20190116A1 (es) 2019-01-16
BR112018072542A2 (pt) 2019-03-26
US20170320854A1 (en) 2017-11-09
ECSP18081881A (es) 2018-11-30
ES2866109T3 (es) 2021-10-19
EP3452463A1 (en) 2019-03-13
JP6932140B2 (ja) 2021-09-08
US10472348B2 (en) 2019-11-12
HUE053908T2 (hu) 2021-07-28
LT3452463T (lt) 2021-04-26
US20190144423A1 (en) 2019-05-16
MA44851B1 (fr) 2021-09-30
GEP20207158B (en) 2020-10-12
UA123791C2 (uk) 2021-06-02
UY37220A (es) 2017-11-30
MX381787B (es) 2025-03-13
CU24567B1 (es) 2022-01-13
EP3452463B1 (en) 2021-03-24
JOP20170105B1 (ar) 2022-03-14

Similar Documents

Publication Publication Date Title
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
CY1120941T1 (el) Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1125245T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX385332B (es) Moduladores de ror-gamma.
EA201990400A1 (ru) Соединения и композиции и их применение
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA202090414A1 (ru) Соединения и их применение
CY1125179T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεïνης ενεργοποιησης της 5-λιποξυγενασης (flap)
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды